The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials

The Journal of Clinical Psychiatry
S R MarderG Chouinard

Abstract

In two double-blind trials conducted in North America, 513 patients with chronic schizophrenia received risperidone, haloperidol, or placebo. In the present study, combined data from the two trials were analyzed. Patients were randomly assigned to receive placebo, fixed doses of risperidone (2, 6, 10, and 16 mg/day) or 20 mg/day of haloperidol for 8 weeks. Factor analysis of scores on the Positive and Negative Syndrome Scale (PANSS) produced five dimensions (negative symptoms, positive symptoms, disorganized thought, uncontrolled hostility/excitement, and anxiety/depression), similar to the five dimensions of previous factor-analytic studies of PANSS data. Mean changes (symptom reductions) in PANSS factor scores from baseline to treatment Weeks 6 and 8 were significantly greater in patients receiving 6-16 mg/day of risperidone than in patients receiving placebo or haloperidol. The advantages of risperidone were greatest for negative symptoms, uncontrolled hostility/excitement, and anxiety/depression. Even at the lowest dose, 2 mg/day, risperidone was significantly (p < or = .05) superior to haloperidol in reducing negative symptoms. The differences in outcomes between risperidone and haloperidol on PANSS scores were not related...Continue Reading

Citations

Nov 4, 2010·Social Psychiatry and Psychiatric Epidemiology·Yu-Tao XiangGabor S Ungvari
Jan 12, 2012·Psychopharmacology·Philippe CorbeilEmmanuelle Pourcher
Apr 7, 2005·European Archives of Psychiatry and Clinical Neuroscience·Hans-Jürgen Möller
Jul 5, 2005·European Archives of Psychiatry and Clinical Neuroscience·Hans-Jürgen Möller
Jul 21, 2004·Current Psychiatry Reports·Jacqueline E MullerDaniel J Stein
Nov 2, 2013·Revista de psiquiatrí́a y salud mental·M Paz García-Portilla, Julio Bobes
Sep 18, 2004·Schizophrenia Research·Penny E MohrPeter J Neumann
May 24, 2005·Schizophrenia Research·Robert A LasserJohn M Kane
May 15, 2002·Psychiatry Research·Allison M CameronLaurie B Geffen
Feb 21, 2002·Progress in Neuro-psychopharmacology & Biological Psychiatry·Norio Yasui-FurukoriKoichi Otani
Nov 1, 2002·Schizophrenia Research·Julie A KreyenbuhlRobert R Conley
Mar 22, 2003·Schizophrenia Research·Robin EmsleyUNKNOWN RIS-INT-35 Early Psychosis Global Working Group
Aug 2, 2003·Schizophrenia Research·Richard James DrakeShôn Lewis
Apr 22, 2004·Schizophrenia Research·Jean-Pierre LindenmayerVirginia L Stauffer
Apr 6, 1999·Schizophrenia Research·G D Tollefson, T M Sanger
Sep 17, 2002·European Psychiatry : the Journal of the Association of European Psychiatrists·L Hosák, R Bahbouh
Sep 5, 2001·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·A Aleman, R S Kahn
Apr 2, 2009·Psychological Medicine·S LeuchtJ M Davis
Jun 13, 2013·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Robert A LasserJean-Pierre Lindenmayer
Jul 5, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·John M DavisIra D Glick
Jan 5, 2002·The New England Journal of Medicine·John G CsernanskyUNKNOWN Risperidone-USA-79 Study Group
Dec 29, 2009·Journal of Child and Adolescent Psychopharmacology·Magali HaasStuart F Kushner
Jan 11, 2008·Schizophrenia Bulletin·Robert P McMahonWilliam T Carpenter
Nov 18, 2008·Schizophrenia Bulletin·Peter F BuckleyDavid J Castle
Jan 20, 2012·Schizophrenia Bulletin·Ulrich ReininghausRichard P Bentall
Jul 19, 2001·International Clinical Psychopharmacology·S KasperUNKNOWN RODOS Investigator Group
Jun 18, 2004·International Clinical Psychopharmacology·Martin TurnerMariëlle Eerdekens
Jun 15, 2007·Cognitive and Behavioral Neurology : Official Journal of the Society for Behavioral and Cognitive Neurology·Matthew S MilakIgor I Galynker
May 1, 2012·Cognitive and Behavioral Neurology : Official Journal of the Society for Behavioral and Cognitive Neurology·Juan Carlos SanzJuan José Marín
Jun 12, 2008·International Clinical Psychopharmacology·Carla M CanusoGeorge M Simpson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here